

15. ADDITIONAL INFORMATION

15.1 SHARE CAPITAL

- (i) The share capital of our Company and our subsidiaries as at the LPD and changes in their respective share capital for the Financial Years Under Review and up to the LPD are set out in Sections 6.4 and 6.5 of this Prospectus.
- (ii) No securities will be allotted, issued or offered on the basis of this Prospectus later than 6 months after the date of issue of this Prospectus.
- (iii) As at the date of this Prospectus, we have only one class of shares in our Company, namely ordinary shares, all of which rank equally with one another. There are no special rights attached to our Shares.
- (iv) Save for the new Shares issued pursuant to the Acquisitions as disclosed in Section 6.2 of this Prospectus and the outstanding registered capital of Crest Suzhou as disclosed in Section 6.5.10, no shares, debentures, outstanding warrants, options or convertible securities or uncalled capital of our Company or any of our subsidiaries have been issued or proposed to be issued as fully or partly paid-up, in cash or otherwise than in cash, within the 3 years preceding the LPD.
- (v) As at the date of this Prospectus, save for our Pink Form Shares as disclosed in Section 4.3.1(ii) of this Prospectus, there is currently no other scheme involving our Directors and employees in the share capital of our Company or any of our subsidiaries.
- (vi) None of the share capital of our Company or any of our subsidiaries is under option or agreed conditionally or unconditionally to be put under option, as at the date of this Prospectus.

15.2 EXTRACTS OF OUR CONSTITUTION

The following provisions are extracted from our Constitution which complies with the Listing Requirements, the Act and the Rules of Bursa Depository. The words, terms and expressions appearing in the following provisions will bear the same meanings used in our Constitution unless they are otherwise defined herein or the context otherwise requires.

15.2.1 Director's remuneration

Clause 105(g) – Alternate Director

“(g) An Alternate Director shall not be entitled to receive remuneration otherwise than out of the remuneration of the Director appoint him.”

Clause 106 – Directors' remuneration

“The Directors shall be paid by way of remuneration for their services, such fees and any other benefits payable to such directors (if any) subject to annual shareholder approval at General Meeting and such remuneration shall be divided among the Directors in such proportions and manner as the Directors may determine, PROVIDED ALWAYS that:

- (a) save as provided in this Clause 106(a) hereof, an executive Director shall, subject to the terms and any agreement (if any) entered into any particular case, receive such remuneration as the Directors may determine. All remuneration, other than the fees provided for in this Clause 106(a) hereof, payable to the non-executive Directors shall be determined by a resolution of the Company in General Meeting;

15. ADDITIONAL INFORMATION (Cont'd)

- (b) fees payable to Non-Executive Directors shall be a fixed sum, and not by a commission on or percentage of profits or turnover;
- (c) salaries payable to Executive Directors may not include a commission or on percentage of turnover;
- (d) fees and any benefits payable to Directors shall be subject to annual shareholder approval at a General Meeting, where notice of the proposed increase has been given in the notice convening the meeting; and
- (e) the fees and / or benefits payable to Non-Executive Directors who are also Director(s) of the subsidiaries include but are not limited to directors' fees, meeting allowances, travelling allowances and benefits, but does not include insurance premium or any issue of securities."

Clause 107 – Reimbursement of expenses

"The Directors shall be paid all their travelling and other expenses properly and necessary expended by them in and about the business of the Company including their travelling and other expenses incurred in attending Board of Directors' Meeting or any committee meeting of the Directors or General Meeting of the Company."

Clause 108

"If any Director being willing shall be called upon to perform extra services or to make any special exertions in going or residing away from his usual place of business or residence for any of the purposes of the Company as a member of a committee of Directors, the Company may remunerate the Director so doing either by a fixed sum or otherwise (other than by a sum to include a commission on or percentage of turnover) as may be determined by the Board in General Meeting and such remuneration may be either in addition to or in substitution for his or their share in the remuneration from time to time provided for the Directors. Extra remuneration payable to Non-Executive Director(s) shall not include a commission or percentage of turnover or profits."

Clause 115 - Power to maintain Pension or Fund

"The Directors may establish or arrange any contributory or non-contributory pension superannuation fund or life assurance scheme for the benefit of, or pay a gratuity, pension or emolument to any person who is or has been employed by or in the service of the Company or any subsidiary of the Company, or to any person who is or has been a Director or other officer of and holds or has held salaried employment in the Company or any such subsidiary, and to widow, family or dependents of any such person. The Directors may also subscribe to any association or fund which they consider to be for the benefit of the Company or any such subsidiary or any such persons as aforesaid and make payments for or towards any hospital or scholastic expenses, and make payments for or towards any hospital or any Director holding such salaried employment shall be entitled to retain any benefit received by him hereunder subject only, where the provisions of the Act requires, to proper disclosure to the Members and the approval of the Company in General Meeting."

Clause 149 – Managing Director

"The remuneration of the Managing Director shall, subject to the terms of any agreement entered into in any particular case may be by way of salary or commission or participation in profits or otherwise or by any or all of these modes but such remuneration shall not include a commission on or percentage of turnover but it may be a term of their appointment that they shall receive pension, gratuity or other benefits upon their retirement."

15. ADDITIONAL INFORMATION (Cont'd)

15.2.2 Voting and Borrowing powers of DirectorsClause 113 – Directors' borrowing power and issue debentures

"The Directors may exercise all the powers of the Company to borrow money and to mortgage or charge its undertaking, property and uncalled capital, or any part thereof, and to issue debentures and other Securities whether outright or as security for any debt, liability or obligation of the Company or any person or persons or of any company, whether or not having powers or engaged or intending to engage in business similar to those of the Company, including (without limitation) any company which is for the time being associated or allied with the Company in business or which is the holding company or a subsidiary (as defined in Section 4 of the Act) or an associated company."

Clause 129 – Chairman to have casting vote

"Subject to this Constitution any question arising at any meeting of Directors shall be decided by a majority of votes and a determination by a majority of Directors shall for all purposes be deemed a determination of the Directors. In case of an equality of votes, the Chairman of the meeting shall have a second or casting vote except where the quorum is made up of only two (2) Directors and only such a quorum is present at the meeting or where only two (2) Directors are competent to vote on the question at issue."

Clause 133 - Restriction on voting

"A Director shall not vote in regard to any contract or proposed contract or arrangement in which he has, directly or indirectly, an interest. Without prejudice to the generality of the foregoing, a Director shall also not vote in regard to any contract or proposed contract or arrangement with any other company in which he is interested either as an officer of that other company or as a holder of shares or other securities in that other company."

Clause 134 - Director may vote on the giving of security or indemnity where he is interested

"Subject to Clause 133, a Director may vote in respect of:

- (a) any arrangement for giving the Director himself or any other Director any security or indemnity in respect of money lent by him to or obligations undertaken by him for the benefit of the Company; and
- (b) any arrangement for the giving by the Company of any security to a third party in respect of a debt or obligation of the Company for which the Director himself or any other Director has assumed responsibility in whole or in part under a guarantee or indemnity or by a deposit of security.

By Ordinary Resolution of the Company, the provisions of this Clause may at any time be suspended or relaxed to any extent and either generally or in respect of any particular contract, arrangement or transaction, and any particular contract, arrangement or transaction carried out in contravention of this Clause may be ratified."

15. ADDITIONAL INFORMATION (Cont'd)Clause 135

“A Director of the Company may be or become a director or other officer of or otherwise interested in any corporation promoted by the Company or in which the Company may be interested as shareholder or otherwise or any corporation which is directly and indirectly interested in the Company as shareholder or otherwise and no such Director shall be accountable to the Company for any remuneration or other benefit received by him as a director or officer of, or from his interest in, such corporation unless the Company otherwise directs at the time of his appointment. The Directors may exercise the voting power conferred by the shares or other interest in any such other corporation held or owned by the Company, or exercisable by them as Directors of such other corporation, in such manner and in all aspects as they may think fit (including the exercise thereof in any favour of any resolution appointing themselves or any of the Directors or other officers of such corporation), and any Director may vote in favour of the exercise of such voting rights in manner aforesaid notwithstanding that he may be or is about to be appointed a director or other officer of such corporation and as such is or may become interested in the exercise of such voting rights in the manner aforesaid.”

15.2.3 Changes in share capital, rights, preferences, restrictions attached to each class of securities relating to voting, dividend, liquidation and any special rights and variation of class rightsClause E

“The share capital of the Company is its issued share capital. The capital of the Company may be increased and the shares in the capital for the time being either forming part of the original capital or of any increase thereof may be divided from time to time into several classes and there may be attached to any of such shares such preferential deferred qualified or special rights privileges or conditions or restrictions as to dividend, capital, voting or otherwise as may be determined upon by or in accordance with this Constitution. The Company shall have power to issue shares at any time and any part of the capital may be issued as fully or partly paid up, and every issue of shares shall (unless the conditions of issue shall otherwise expressly declare) be subject to the foregoing provisions.”

Clause 5 – Allotment of Shares and power to issue Shares

“Without prejudice to any special rights previously conferred on the holders of any existing shares or class of shares and subject to the provisions of this Constitution, the Act and the provisions of any resolution of the Company, shares in the Company may be issued by the Directors, who may allot, or otherwise dispose of such shares to such persons, on such terms and conditions, with such preferred, deferred or other special rights, limited or conditional voting rights and subject to such restrictions and at such times as the Directors may determine but the Directors in making any issue of shares shall comply with the following conditions:-

- (a) in the case of shares of a class, other than ordinary shares, no special rights shall be attached until the same have been expressed in this Constitution and in the resolution creating the same;
- (b) every issue of shares or options to Directors and/or employees shall be approved by Members in General Meeting and such approval shall specifically detail the amount of shares or options to be issued to such Directors and/or employees;

15. ADDITIONAL INFORMATION (Cont'd)

- (c) except in the case an issue of securities on a pro rata basis to shareholders or pursuant to a back-to-back placement undertaken in compliance with the Listing Requirements or pursuant to a dividend reinvestment scheme, a Director of the Company shall not participate, directly or indirectly, in an issue of ordinary shares or other securities with rights of conversion to ordinary shares or in a share issuance scheme unless the shareholders of the Company in General Meeting have approved the specific allotment to be made to the Director and the Director has abstained from voting on the relevant resolution;
- (d) without limiting the generality of Section 76 of the Act, the Company must not issue any ordinary shares or other securities with rights of conversion to ordinary shares if the total number of those shares or securities, when aggregated with the total number of any such shares or securities which the Company has issued during the preceding twelve (12) months, exceeds ten percent (10%) of the total number of issued shares (excluding treasury shares) of the Company, except where the shares or securities are issued with the prior shareholder approval in a General Meeting of the precise terms and conditions of the issue; and
- (e) in working out the number of shares or securities that may be issued by the Company, if the security is a convertible security, each such security is counted as the maximum number of shares into which it can be converted or exercised.”

Clause 13 – Pre-emptive rights

“Subject to the Listing Requirements and any direction to the contrary that may be given by the Company in a General Meeting, all new Shares or other convertible Securities shall before issue, be offered to such persons as at the date of the offer are entitled to receive notices from the Company of General Meetings in proportion, as nearly as the circumstances admit, to the amount of the existing Shares or Securities to which they are entitled. The offer shall be made by notice specifying the number of Shares or Securities offered, and limiting a time within which the offer, if not accepted, will be deemed to be declined, and, after the expiration of that time, or on the receipt of an intimation from the person to whom the offer is made that he declines to accept the Shares or Securities offered, the Directors may dispose of those Shares or Securities in such manner as they think most beneficial to the Company. The Directors may likewise so dispose of any new Shares or Securities which by reason of the ratio which the new Shares or Securities bear the Shares or Securities held by persons entitled to an offer of new Shares or Securities cannot, in the opinion of the Directors, be conveniently offered under this Constitution.”

Clause 14 – Shares issued for purposes of raising money for the construction of works or building

“Where any shares are issued for the purpose of raising money to defray the expenses of the construction of any works or buildings, or the provision of any plant which cannot be made profitable for a long period, the Company may pay interest on the amount of such share capital as is for the time being paid up for the period and subject to the conditions and restrictions mentioned in Section 130 of the Act and may charge the same to share capital as part of the cost of the construction of any works or buildings or the provision of any plant.”

15. ADDITIONAL INFORMATION (Cont'd)

Clause 16 – Purchase by Company of its own Shares

“Subject to the provisions of the Act and the requirements and any rules, regulations and/or guidelines thereunder issued by the Exchange and/or any other relevant authority in respect thereof for the time being in force, the Company shall have the power and may purchase its own Shares and thereafter the Directors may resolve and shall have the fullest power to deal with such purchased shares in accordance with the provisions of the Act and such other relevant laws, regulation and/or guidelines. Any ordinary Shares in the Company so purchased by the Company shall be dealt with in accordance with the provisions of the Act, the requirements and any rules, regulations and guidelines thereunder issued by the Exchange and/or any other relevant authority in respect thereof.”

Clause 36 – Transfer of securities

“The instrument of transfer of any listed Securities shall be in writing and in the form approved in the Rules and shall be executed by or on behalf of the transferor and transferee, and the transferor shall be deemed to remain the holder of the securities until the name of the transferee is entered in the Record of Depositors in respect thereof. The transfer of any listed Securities or class of listed Securities of the Company shall be by way of book entry by the Depository in accordance with the Rules and notwithstanding Sections 105, 106 and 110 of the Act, but subject to Subsection 148(2) of the Act and any exemption may be made from compliance with Subsection 148(1) of the Act, the Company shall be precluded from registering and effecting any transfer of listed Securities.”

Clause 37

“Subject to the Rules and Listing Requirements, the transfer of any Securities may be suspended at such times and for such periods as the Directors may from time to time determine. Ten (10) Market Days’ notice, or such other period as may from time to time be specified by the Exchange governing the Register concerned, of intention to close the Register shall be given to the Exchange. At least three (3) Market Days’ or such other period as may from time to time be specified by the governing authority, prior notice shall be given to the Bursa Depository to prepare the appropriate Record of Depositors.”

Clause 38

“The Bursa Depository may refuse to register any transfer of Deposited Security that does not comply with the Central Depositories Act and the Rules. No Securities shall in any circumstances be transferred to any infant, bankrupt or person of unsound mind.”

Clause 39

“Subject to the provisions of this Constitution, the Directors may recognise a renunciation of the allotment of any share by the allottee thereof in favour of some other person.”

15. ADDITIONAL INFORMATION (Cont'd)Clause 40

“Subject to any law in Malaysia for the time being in force, neither the Company nor the Directors nor any of its officers shall incur any liability for the act of the Bursa Depository in registering or acting upon a transfer of Securities apparently made by a Member or any person entitled to the Securities by reason of death, bankruptcy or insanity of a Member although the same may, by reason of any fraud or other causes not known to the Company or the Directors or the Bursa Depository or other officers, be legally inoperative or insufficient to pass the property in the Securities proposed or professed to be transferred, and although the transfer may as between the transferor Member and the transferee, be liable to be set aside and notwithstanding that the Company may have notice that such instrument or transfer was signed or executed and delivered by the transferor Member in the blank as to the name of the transferee, of the particulars of the Securities transferred or otherwise in defective manner. And in every case, the person registered as transferee, his executors, administrators and assignees alone shall be entitled to be recognised as the holder of such Securities and the previous holder shall, so far as the Company is concerned, be deemed to have transferred his whole title thereto.”

Clause 47 – Modification of class rights

“The Company may from time to time by Ordinary Resolution increase the share capital by the creation and issue of new Shares, such new capital to be of such amount to be divided into Shares of such respective amounts and to carry such rights or to be subject to such conditions or restrictions in regard to dividend, return of capital or otherwise as the Company may direct in the resolution authorising such increase.”

Clause 49 – Modification of class rights

“If at any time, the share capital by reason of the issue of preference shares or otherwise is divided into different classes the repayment of such preferred capital or all or any of the rights and privileges attached to each class may subject to the provisions of the Act be varied modified commuted affected abrogated or dealt with by a written consent representing not less than seventy-five per centum (75%) of the total voting rights of the preference shareholders or by Special Resolution passed by the holders at least seventy-five per centum (75%) of the total voting rights at a separate General Meeting of the holders of that class and all the provisions hereinafter contained as to General Meetings shall equally apply to every such meeting except that the quorum hereof shall be Members holding or representing by proxy at least one-third (1/3) of the issued shares of the class. Provided however that in the event of the necessary majority for such a Special Resolution not having been obtained in the manner aforesaid consent in writing may be secured from Members holding at least seventy-five per centum (75%) of the total voting rights and such consent if obtained within two (2) months from the date of the separate General Meeting shall have the force and validity of a resolution duly carried by a vote in person or by proxy.”

[The rest of this page has been intentionally left blank]

15. ADDITIONAL INFORMATION (Cont'd)Clause 51 – Alteration of Capital

"The Company may alter its share capital in any one or more of the following ways by passing an Ordinary Resolution:

- (a) to consolidate and divide all or any of its share capital, the proportion between the amount paid and the amount, if any, unpaid on each subdivided share shall be the same as it was in the case of the share from which the subdivided Share is derived;
- (b) to convert all or any of its paid-up Shares into stock and may reconvert that stock into paid-up Shares;
- (c) to subdivide its share capital or any part thereof, whatever is in the subdivision, the proportions between the amount paid and the amount, if any, unpaid on each subdivided Share shall be the same as it was in the case of the Shares from which the subdivided Share is derived;
- (d) to increase the share capital by such sum to be divided into shares of such amount as the resolution shall prescribe; or
- (e) to cancel any Shares which at the date of the passing of the resolution which have been forfeited and diminish the amount of its Share capital by the amount of the Shares so cancelled."

Clause 52 – Power to reduce capital

"Notwithstanding any other authorisation and consent that may be required by the provisions of the Act, the Company may reduce its share capital by:

- (a) Special Resolution and confirmation by the High Court in accordance with Section 116 of the Act; or
- (b) Special Resolution supported by a solvency statement in accordance with Section 117 of the Act."

Clause 53 – Share buy-back and financial assistance

Subject always to the provisions of this Constitution, the Act and the Listing Requirements, the Company shall be empowered to purchase its own Shares provided that such power shall be exercised if:

- (a) the Company is solvent at the date of the purchase and will not become insolvent by incurring the debts involved in the obligation to pay for the Shares so purchased;
- (b) the purchase is made through the stock exchange on which Shares of the Company are quoted and in accordance with the relevant rules of the stock exchange; and
- (c) the purchase is made in good faith and in the interests of the Company.

15. ADDITIONAL INFORMATION (Cont'd)

Where the Company has purchased its own Shares, the Directors may, subject to and in accordance with the Act and the Listing Requirements or any other stock exchange upon which the Company's Shares are listed and any other authority:

- (a) cancel the Shares so purchased; and/or
- (b) retain the Shares so purchase in treasury (the "Treasury Shares");
- (c) retain part of the Shares and cancel the remainder of the Shares so purchased; and/or
- (d) resell to the market.

15.3 DEPOSITED SECURITIES AND RIGHTS OF DEPOSITORS

Pursuant to Section 14(1) of the SICDA, Bursa Securities has prescribed our Shares as securities to be deposited into the CDS. Following this, we will deposit our Shares directly with Bursa Depository and any dealings in our Shares will be carried out in accordance with the SICDA and Depository Rules. We will not issue any share certificates to successful applicants.

Dealing in Shares deposited with Bursa Depository may only be effected by a Depositor by means of entries in the securities account of that Depositor.

A Depositor whose name appears in the Record of Depositors maintained by Bursa Depository in respect of our Shares will be deemed to be a shareholder of our Company and will be entitled to all rights, benefits, powers and privileges and be subject to all liabilities, duties and obligations in respect of, or arising from, such Shares.

15.4 LIMITATION ON THE RIGHT TO HOLD SECURITIES AND/OR EXERCISE VOTING RIGHTS

Subject to Section 15.3 above and Clauses 81 and 84(c) which have been reproduced below from our Constitution, there is no limitation on the right to own our Shares, including any limitation on the right of a non-resident or foreign shareholders to hold or exercise voting rights on our Shares which is imposed by Malaysian law or by our Constitution.

Clause 81 – Vote of Member of unsound mind

A Member who is of unsound mind or whose person or estate is liable to be dealt with in any way under the law relating to mental disorder may vote, whether on a show of hands or on a poll, by his committee or by such other person who properly has the management of his estate, and any such committee or other person may vote by proxy or attorney and any person entitled under this Constitution to transfer any Shares may vote at any General Meeting in respect thereof in the same manner as if he was the registered holder of such Shares provided that forty-eight (48) hours at the least before the time of holding the General Meeting or adjourned General Meeting as the case may be at which he proposes to vote, he shall satisfy the Directors of his right to transfer such Shares unless the Directors shall have previously admitted his right to vote at such General Meeting in respect thereof.

Clause 84(c) - No Member to vote unless calls paid

Subject to Clauses 58, 59 and 60 above, a Member of the Company shall be entitled to be present and to vote at any General Meeting in respect of any Share or Shares upon which all calls due to the Company have been paid. No person shall be entitled to be present or to vote on any resolution either as a Member or otherwise as a proxy, or attorney, or representative at any General Meeting or demand a poll or be reckoned in the quorum in respect of any Shares upon which calls are due and unpaid.

15. ADDITIONAL INFORMATION (Cont'd)

15.5 REPATRIATION OF CAPITAL, REMITTANCE OF PROFIT AND TAXATION

(i) Malaysia

There are no significant restrictions on remittances of profit by Crest Lab, Crest Nanosolutions, Crest Systems, Matrix Innovations, Matrix Optics, Crest Analytic and/or Matrix Biosciences to its shareholder(s) or Crest, subject to anti-money laundering; counter-financing of terrorism and taxation related considerations under the relevant and applicable Malaysian laws.

Under the Act, a company may only pay dividends to its shareholders out of profits of the company available if the company is solvent. Such distribution must be authorised by the board of directors of the company and if the directors are satisfied that the company will be solvent immediately after the distribution is made.

All corporations in Malaysia are required to adopt a single-tier dividend. All dividends distributed by Malaysian resident companies under a single-tier dividend are tax-exempt in the hands of shareholders. Further, the Malaysian Government does not levy withholding tax on dividend payments. Therefore, there is no withholding tax imposed on dividends paid to non-residents by Malaysian resident companies. There is no Malaysian capital gains tax arising from the disposal of listed shares.

(ii) Singapore

There are generally no restrictions or time frame stipulated on the repatriation or remittance of profits, whether in the form of dividends or interests, or capital (meaning funds in general, instead of the share capital of Crest Innovation and/or Crest Upstar) into or out of Singapore, or significant restrictions on remittances, capital movements and foreign currency exchange transactions, by Crest Innovation and/or Crest Upstar to its shareholder(s), subject to anti-money laundering; counter-financing of terrorism; taxation related considerations under the relevant and applicable Singapore laws.

Generally, repatriation of profits and remittance of funds out of a company's share capital is entirely dependent on the ability of such company to pay funds to its shareholder(s) in accordance with its constitution and the provisions of the Companies Act 1967 of Singapore ("**Companies Act**"). Under Singapore laws, Crest Innovation and/or Crest Upstar may repatriate capital to their shareholders (including foreign shareholders) if the same is effected through a capital reduction exercise or a share buyback in accordance with its constitution and the Companies Act.

Under the Companies Act, Crest Innovation and/or Crest Upstar are permitted to remit profits to their shareholders if the same is effected through payment of dividends. Under section 403 of the Companies Act, a company may only pay dividends to shareholders out of profits of the company. Crest Innovation and/or Crest Upstar may declare dividends in accordance with its constitution and the directors may make a recommended rate to be paid as dividends, which will be voted on and approved by shareholders at the company's annual general meeting or extraordinary general meeting. There is no requirement to withhold tax on such dividend payments, whether the same is paid to resident shareholders or non-resident shareholders.

Under Section 13(1)(za) of the Income Tax Act 1947 of Singapore ("**Income Tax Act**"), Singapore adopts the one-tier corporate taxation system whereby any dividends paid on or after 1st January 2008 by any company resident in Singapore is exempt from income tax, so long as said dividend is not paid wholly or in part out of income exempted from tax. Such dividends are tax-exempt in the hands of the shareholders, regardless of whether the shareholder is a company or an individual and whether or not the shareholder is a Singapore tax resident. Further, as dividend payments is an exempted income under the Income Tax Act, dividend payments to both resident and non-resident shareholders will not be subject to withholding tax.

15. ADDITIONAL INFORMATION (Cont'd)

(iii) PRC

Pursuant to the Foreign Investment Law of PRC, foreign investors may in accordance with law, freely remit into or out of the PRC, their capital contributions, profits, capital gains, income from asset disposal, intellectual property royalties, compensation or indemnification obtained in accordance with law, liquidation income and so forth, that are made or obtained in the PRC, in RMB or other foreign currency.

The key regulation governing foreign exchange in the PRC is the Foreign Exchange Administration Regulations which became effective on 5 August 2008. Pursuant to the Foreign Exchange Administration Regulations, foreign exchange transactions are categorized into current account items and capital account items. Payments of current account items, such as trade and service-related foreign exchange transactions and profits, can be made freely without prior approval from the State Administration of Foreign Exchange (the “SAFE”) so long as they are genuine and legitimate transactions and certain procedural requirements are complied with. However, payments of capital account items, such as capital transfers, loans and repatriation of investments can only be made with SAFE’s prior approval or prior registration with SAFE for conversion of RMB into other foreign currency and remittance of the foreign currency outside the PRC.

Under PRC Company Law, Crest Suzhou may only make dividend payments out of its accumulated profits. Prior to distributing dividends, Crest Suzhou is required to, amongst others, pay corporate income tax at the rate of 25%, make up the accumulated losses in previous years (if any) and set aside 10% of its after-tax profit to a statutory surplus reserve fund until such reserve fund reaches 50% of its registered capital.

Pursuant to the PRC Enterprise Income Tax Law and its Implementing Regulation (the “EIT Law”) which became effective on 1 January 2008 and subsequently amended in 2017 and 2018, non-resident enterprises (i.e. an entity established under foreign law whose de facto management bodies are not within the PRC but which have an establishment or place of business in the PRC, or which have no such establishment or place of business but have income generated from within the PRC) are subject to income tax for the income deriving from or accruing in the PRC, for example, the dividends received by the foreign shareholders of Crest Suzhou and other gains from investment received by the foreign shareholders of Crest Suzhou. The tax rate is generally 10% and Crest Suzhou will be responsible to withhold such tax prior to repatriating any dividends or profits to its foreign shareholders.

(iv) Thailand

Capital of a company incorporated in Thailand (“**Thai Company**”) may be returned to its shareholders pursuant to a capital reduction exercise or dissolution of the company, in accordance with the Civil and Commercial Code of Thailand and the company’s articles of association. There are no restrictions on the repatriation of reduced capital from Crest Thailand to its foreign shareholders or the repatriation of capital return due to dissolution of company from Crest Thailand (if dissolved) to its foreign shareholders, and no approval is required for such repatriation under the Exchange Control Act of Thailand (B.E. 2485) (1942), as amended (the “**Exchange Control Act**”).

Dividend payments in Thailand are categorized as payments for goods and services and are allowed up to the amount of the obligations imposed upon the payer. Under the Civil and Commercial Code of Thailand, dividends can be declared and paid, in the case of final dividends, by the resolution of a meeting of its shareholders and in the case of interim dividends, by the resolution of the board of directors.

15. ADDITIONAL INFORMATION (Cont'd)

There are no restrictions on or approvals required for the repatriation of dividend payments by Crest Thailand to Malaysia under the Exchange Control Act, save that dividends can only be paid out of the profits of Crest Thailand. The dividend payments made by Crest Thailand to its foreign shareholders are deemed taxable income and subject to a withholding tax at the rate of 10% of the taxable income.

Dividend payments and the repatriation of capital proceeds pursuant to a capital reduction exercise or dissolution of a Thai Company to its foreign shareholders must be converted into foreign currency prior to outward remittance from Thailand. Such foreign exchange transaction must be conducted through commercial banks or certain other entities which the Bank of Thailand has authorized to conduct foreign exchange transactions as authorized agents of the Bank of Thailand.

If the amount per remittance is less than US\$200,000 or its equivalent in the relevant currency, such remittance may be made without filing supporting documents unless requested by the authorised commercial bank. If the amount is US\$200,000 or its equivalent in the relevant currency or more, particulars of such foreign exchange transaction and supporting evidence will need to be submitted to the authorized commercial bank, such documents may include:

- (a) in the case of dividend payments, resolutions from a meeting of its shareholders or its board of directors, and an up-to-date list of the shareholders of the Thai Company; and
- (b) in the case of repatriation of reduced capital or capital return due to dissolution of the Thai Company, the affidavit showing the reduced capital or minutes of the shareholders' meeting or evidence certifying the completion of liquidation issued by a liquidator or minutes of the shareholders' meeting approving the dissolution of the Thai Company.

[The rest of this page has been intentionally left blank]

15. ADDITIONAL INFORMATION (Cont'd)

15.6 MATERIAL CONTRACTS

Save as disclosed below, our Group has not entered into any material contracts (including contracts not in writing) that are not in the ordinary course of our Group's business within the Financial Years Under Review and up to the date of this Prospectus:

- (i) Conditional share sale agreement dated 17 January 2024 entered into by the Crest Vendors (as the vendors) and our Company (as the purchaser) for the acquisition of the share capital held by the Crest Vendors in Crest Lab, Crest Systems, Matrix Innovations, Matrix Optics and Crest Analytic, respectively, comprising of 1,951,000 ordinary shares for a purchase consideration of RM25,984,279 which shall be satisfied by the issuance of 519,685,580 new ordinary shares in our Company to the Crest Vendors at an issue price of RM0.05 each, which was completed on [●];
- (ii) Conditional share sale agreement dated 17 January 2024 entered into by the Crest Vendors (as the vendors) and our Company (as the purchaser) for the acquisition of the entire issued share capital in Matrix Biosciences, comprising of 100 ordinary shares for a purchase consideration of RM3, which was completed on [●];
- (iii) Conditional share sale agreement dated 17 January 2024 entered into by the Crest Vendors and KKY (as the vendors) and our Company (as the purchaser) for the acquisition of the entire issued share capital in Crest Nanosolutions, comprising of 500,000 ordinary shares for a purchase consideration of RM5,393,837 which shall be satisfied by the issuance of 107,876,740 new ordinary shares in our Company to the Crest Vendors and KKY at an issue price of RM0.05 each, which was completed on [●];
- (iv) Conditional sale and purchase agreement dated 17 January 2024 entered into by the Crest Vendors (as the vendors) and our Company (as the purchaser) for the acquisition of 70.00% equity interest in Crest Innovation, comprising of 40,000 ordinary shares for a purchase consideration of RM1,123,777 which shall be satisfied by the issuance of 22,475,540 new ordinary shares in our Company to the Crest Vendors at an issue price of RM0.05 each, which was completed on [●];
- (v) Conditional sale and purchase agreement dated 17 January 2024 entered into by the Crest Vendors (as the vendors) and our Company (as the purchaser) for the acquisition of the entire issued share capital in Crest Upstar, comprising of 1,500 ordinary shares for a purchase consideration of SGD3, which was completed on [●];
- (vi) Conditional equity transfer agreement dated 17 January 2024 entered into by the Crest Vendors (as the vendors) and our Company (as the purchaser) for the acquisition of 80.00% equity interest in Crest Suzhou for a purchase consideration of RM3,833,317 which shall be satisfied by the issuance of 76,666,340 new ordinary shares in our Company to the Crest Vendors at an issue price of RM0.05 each, which was completed on [●];
- (vii) Conditional share sale agreement dated 17 January 2024 entered into by the Crest Vendors (as the vendors) and our Company (as the purchaser) for the acquisition of 49.00% equity interest in Crest Thailand, comprising of 60,000 ordinary shares for a purchase consideration of RM409,375 which shall be satisfied by the issuance of 8,187,500 new ordinary shares in our Company to the Crest Vendors at an issue price of RM0.05 each, which was completed on [●]; and
- (viii) Underwriting Agreement dated [●] entered into between our Company and MIDF Investment as the Underwriter for the underwriting of up to 56,264,000 Issue Shares under the Public Issue.

15. ADDITIONAL INFORMATION (Cont'd)

15.7 MATERIAL LITIGATION

As at the LPD, our Group is not involved in any material litigation, claim or arbitration, either as plaintiff, defendant or third party, including those relating to bankruptcy, receivership or similar proceedings which may have or have had a material adverse effect on the business or financial position of our Group. Our Directors confirm that there are no proceedings pending or threatened or of any fact likely to give rise to any proceedings which might materially and adversely affect our financial or business position.

15.8 CONSENTS

- (i) The written consents of our Principal Adviser, Sponsor, Underwriter, Placement Agent, Company Secretaries, Solicitors, Share Registrar and Issuing House as listed in the Corporate Directory of this Prospectus for the inclusion in this Prospectus of their names in the form and context in which such names appear have been given before the issuance of this Prospectus and have not subsequently been withdrawn.
- (ii) The written consent of our Auditors and Reporting Accountants for the inclusion of its name, the Accountants' Report and the Reporting Accountants' Report on the Pro Forma Combined Statements of Financial Position of our Group and all references thereto in the form and context in which they are contained in this Prospectus have been given before the issuance of this Prospectus and have not subsequently been withdrawn.
- (iii) The written consent of our IMR for the inclusion of its name, the IMR Report and all references thereto in the form and context in which they are contained in this Prospectus has been given before the issuance of this Prospectus and has not subsequently been withdrawn.

15.9 DOCUMENTS AVAILABLE FOR INSPECTION

Copies of the following documents may be inspected at our registered office at 12th Floor, Menara Symphony, No. 5, Jalan Professor Khoo Kay Kim, Seksyen 13, 46200 Petaling Jaya, Selangor, Malaysia during office hours for a period of 6 months from the date of this Prospectus:

- (i) our Constitution;
- (ii) IMR Report prepared by IMR as included in Section 8 of this Prospectus;
- (iii) Reporting Accountants' Report on the Pro Forma Combined Statements of Financial Position of our Group as at 31 July 2023 as included in Section 13 of this Prospectus;
- (iv) Accountants' Report as included in Section 14 of this Prospectus;
- (v) audited financial statements of our Group for the Financial Years Under Review and the FPE 2023;
- (vi) the material contracts as referred to in Section 15.6 of this Prospectus; and
- (vii) letters of consent referred to in Section 15.8 of this Prospectus.

15. ADDITIONAL INFORMATION (Cont'd)

15.10 RESPONSIBILITY STATEMENTS

Our Directors, Promoters and Selling Shareholders have seen and approved this Prospectus. They collectively and individually accept full responsibility for the accuracy of the information contained in this Prospectus. Having made all reasonable enquiries, and to the best of their knowledge and belief, they confirm there is no false or misleading statement or other facts which if omitted, would make any statement in this Prospectus false or misleading.

MIDF Investment as our Principal Adviser, Sponsor, Underwriter and Placement Agent in relation to our IPO, acknowledges that, based on all available information, and to the best of their knowledge and belief, this Prospectus constitutes a full and true disclosure of all material facts concerning our IPO.

[The rest of this page has been intentionally left blank]

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS

OUR MAJOR LICENCES, PERMITS AND APPROVALS

As at the LPD, a summary of the details of our major licences, permits and approvals for our operations are set out as follows:

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|------------------------|---------------|--|--|---------------------------|---|---|----------------------|
| <u>Malaysia</u> | | | | | | | |
| 1. | Crest Systems | <p>Atomic Energy Licence for:- <u>Class C</u> To manufacture, trade in, produce, process, purchase, own, possess, use, transfer, handle, sell or store irradiating apparatus</p> <p><u>Class E</u> To export or import radioactive materials, nuclear materials, prescribed substances, irradiating apparatus or their wastes</p> <p><u>Class G</u> (a) To dispose of radioactive materials, nuclear materials, prescribed substances or their wastes (b) To store radioactive materials, nuclear materials, prescribed substances or their waste prior to their disposal (c) To decommission a milling installation, nuclear installation, waste treatment facility, irradiating apparatus or sealed source apparatus</p> | Department of Atomic Energy (Atom Malaysia) ("AELB") | 5 June 2022 / 4 June 2024 | LPTA/A/753 | <p>(i) Crest Systems is required to ensure that only YKM (as both the person responsible for the licence and the radiation protection officer) and Dennis Chin Boon Jin (as the supervisor) deal with the AELB.</p> <p>(ii) Crest Systems is required to obtain the approval of the AELB at least 14 days before any recognition, change or recruitment, of the person responsible for the licence, the radiation protection officer, the supervisor or the maintenance operator as the case may be.</p> <p>(iii) Crest Systems is prohibited from making any modifications to all licensed radiation equipment without obtaining the prior approval of the AELB.</p> <p>(iv) This licence is non-transferable.</p> | Complied |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|----------------|--|------------------------------|---------------------------|--|--|----------------------|
| 2. | Crest Analytic | <p><u>Class H</u> For the control of activities not covered by Classes A to G, inclusive</p> <p>Certificate of Registration of Company for government procurement matters</p> <p>The individual authorized by the company to manage the government procurement matters is as follows: (i) Mr. Wong Kam Fui (General Manager)</p> | Ministry of Finance | 31 May 2021 / 6 June 2024 | <p>Certificate No.: K66115871602929389</p> <p>Registration Reference No.: 357-02232380</p> | <p>(i) Any changes to the information submitted by Crest Analytic to the Ministry of Finance must be updated online at Modul Kemaskini Profil at www.eperolehan.gov.my within 21 days from the date of occurrence of such change and a failure to do so may result in action such as item (iii) below.</p> <p>(ii) Crest Analytic is required to ensure that the fields which have been registered under this certificate do not overlap with the fields which have been approved for such companies which: (a) Have the same owner or Board of Directors, management and employees; or (b) Operate at the same premise.</p> <p>(iii) Failure to comply with the conditions of registration and/or field codes may result in the suspension or cancellation of the registration of Crest Analytic and disciplinary action including blacklisted without any notice taken against Crest Analytic, the owner and Board of Directors if it is found that the information given is not true.</p> | Complied |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|---------|--|------------------------------|--------------------------|---|---|----------------------|
| | | | | | | <p>(iv) The registration of Crest Analytic will be suspended or cancelled if it is found that Crest Analytic has committed an offence as follows:</p> <p>(a) It/ its owner/ director/ any of the management members have committed a crime and found to be guilty by the courts of Malaysia or outside Malaysia or suffer from civil liability.</p> <p>(b) It withdraws the offer before the tender is considered or reject an offer.</p> <p>(c) It fails to perform its contractual obligations for contracts which have been signed with the government.</p> <p>(d) It is found to have amended its Certificate of Registration of Company for purposes of fraud.</p> <p>(e) It is found to have allowed its Certificate of Registration of Company to be misused by other individuals/companies.</p> <p>(f) It is found to be involved in price fixing with other companies while participating in a government tender or subcontract without prior consent from the relevant government agency.</p> | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|---------------------|---|------------------------------|-----------------------------------|---|--|----------------------|
| 3. | Crest Nanosolutions | Atomic Energy Licence for:- <u>Class C</u> To manufacture, trade in, produce, process, purchase, own, possess, use, transfer, handle, sell or store irradiating apparatus | AELB | 27 July 2023 / 26 July 2026 | LPTA/A/3530 | (v) Crest Analytic is required to submit an application for renewal of registration three months* prior to the expiry of the registration period. (i) Crest Nanosolutions is required to ensure that only Lyn Meng Keong (as the person responsible for the licence) or Tan Chun Hau (as the radiation protection officer) and the supervisor deal with the AELB. (ii) Crest Nanosolutions is required to obtain the approval of the AELB at least 14 days before any recognition, change or recruitment, of the person responsible for the licence, the radiation protection officer, the supervisor or the maintenance operator as the case may be. (iii) Crest Nanosolutions is prohibited from making any modifications to all licensed radiation equipment without obtaining the prior approval of the AELB. (iv) This licence is non-transferable. | Complied |
| 4. | Crest Lab | Atomic Energy Licence for:- <u>Class C</u> To manufacture, trade in, produce, process, purchase, own, possess, use, transfer, handle, sell or store irradiating apparatus | AELB | 9 November 2022 / 8 November 2025 | LPTA/A/2166 | (i) Crest Lab is required to ensure that only YKM (as the person responsible for the licence) or Teh Beng Choy (as the radiation protection officer) and Lim Jun Lee (as the supervisor) deal with the AELB. | Complied |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|--------------------|--|------------------------------|-----------------------------------|---|---|----------------------|
| | | <p><u>Class E</u> To export or import radioactive materials, nuclear materials, prescribed substances, irradiating apparatus or their wastes</p> <p><u>Class G</u> (a) To dispose of radioactive materials, nuclear materials, prescribed substances or their wastes (b) To store radioactive materials, nuclear materials, prescribed substances or their waste prior to their disposal (c) To decommission a milling installation, nuclear installation, waste treatment facility, irradiating apparatus or sealed source apparatus</p> <p><u>Class H</u> For the control of activities not covered by Classes A to G, inclusive</p> | | | | <p>(ii) Crest Lab is required to obtain the approval of the AELB at least 14 days before any recognition, change or recruitment, of the person responsible for the licence, the radiation protection officer, the supervisor or the maintenance operator as the case may be.</p> <p>(iii) Crest Lab is prohibited from making any modifications to all licensed radiation equipment without obtaining the prior approval of the AELB.</p> <p>(iv) This licence is non-transferable.</p> | |
| 5. | Matrix Innovations | <p>Atomic Energy Licence for:- <u>Class C</u> To manufacture, trade in, produce, process, purchase, own, possess, use, transfer, handle, sell or store irradiating apparatus</p> | AELB | 11 January 2024 / 10 January 2027 | LPTA/A/2256 | (i) Matrix Innovations is required to ensure that only YKM (as the person responsible for the licence) or Yew Li Li (as the radiation protection officer) and the supervisor deal with the AELB. | Complied |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|--------------------|--|------------------------------|-------------------------------|--|--|----------------------|
| 6. | Matrix Innovations | <p>Certificate of Registration of Company for government procurement matters</p> <p>The individuals authorized by the company to manage the government procurement matters are as follows:</p> <ul style="list-style-type: none"> (i) Mr. Au Chun Mun (Director) (ii) Mr. Lim Siong Wai (Director) (iii) Mr. Yap Kian Meng (Director) (iv) Mr. Te Win Ping (Sales Manager) (v) Mr. Heng Yik Ho (Sales Engineer) (vi) Mr. Isfahan Amin Sulaimaan (Sales Engineer) (vii) Mr. Muhammad Adam Ariff Bin Ariffadzillah (Sales Engineer) | Ministry of Finance | 23 March 2021 / 17 April 2024 | <p>Certificate No.: K60113366952867429</p> <p>Registration Reference No.: 357-02002775</p> | <ul style="list-style-type: none"> (ii) Matrix Innovations is required to obtain the approval of the AELB at least 14 days before any recognition, change or recruitment, of the person responsible for the licence, the radiation protection officer, the supervisor or the maintenance operator as the case may be. (iii) Matrix Innovations is prohibited from making any modifications to all licensed radiation equipment without obtaining the prior approval of the AELB. (iv) This licence is non-transferable. | Complied |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|---------|---|------------------------------|--------------------------|---|--|----------------------|
| | | (viii) Mr. Muhammad Nazmi Bin Adnan (Account and Administrative Executive). | | | | <p>(iii) Failure to comply with the conditions of registration and/or field codes may result in the suspension or cancellation of the registration of Matrix Innovations and disciplinary action including blacklisted without any notice taken against Matrix Innovations, the owner and Board of Directors if it is found that the information given is not true.</p> <p>(iv) The registration of Matrix Innovations will be suspended or cancelled if it is found that Matrix Innovations has committed an offence as follows:</p> <p>(a) It/ its owner/ director/ any of the management members have committed a crime and found to be guilty by the courts of Malaysia or outside Malaysia or suffer from civil liability.</p> <p>(b) It withdraws the offer before the tender is considered or reject an offer.</p> <p>(c) It fails to perform its contractual obligations for contracts which have been signed with the government.</p> <p>(d) It is found to have amended its Certificate of Registration of Company for purposes of fraud.</p> <p>(e) It is found to have allowed its Certificate of Registration of Company to be misused by other individuals/ companies.</p> | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|--------------------|---|------------------------------|-------------------------------|---|---|----------------------|
| 7. | Matrix Innovations | Certificate of Registration for import (Form V1) ⁽³⁾ pursuant to section 4(k) of the Electricity Supply Act 1990 | Energy Commission | 4 March 2022 / 4 March 2027 | Approval No. JKKE/KI/22/00033 | <p>(f) It is found to be involved in price fixing with other companies while participating in a government tender or subcontract without prior consent from the relevant government agency.</p> <p>(v) Matrix Innovations is required to submit an application for renewal of registration three months* prior to the expiry of the registration period.</p> | Not applicable |
| 8. | Matrix Optics | Establishment Licence of Matrix Optics as authorized representative, distributor and importer, pursuant to section 24(1) of the Medical Device Act 2012 (Act 737) ("MDA") | Medical Device Authority | 29 April 2021 / 28 April 2024 | Licence No. MDA-1928-WDP121 | <p>(i) This licence is non-transferable.</p> <p>(ii) The licensee shall not permit this licence to be abused in any way by any individual/ another party.</p> <p>(iii) Any changes or amendments to the information concerning licence shall be notified to the Medical Device Authority.</p> <p>(iv) This licence will be suspended or revoked if the licensee is found to have committed the offense as follows: (a) The licensee does not comply with the requirements and conditions for Establishment Licensing under Part III of Act 737 and Part V of the Regulations Medical Device Regulations.</p> | Complied |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance | | | | |
|-------|------------------------|--|------------------------------|--------------------------|---|--------------------------|--------------------------|-----------------------------------|--|--|----------|
| 9. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="726 1422 817 1769"> <tr> <td>Class</td> <td>Class D⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>System⁽²⁾</td> </tr> </table> | Class | Class D ⁽¹⁾ | Group | System ⁽²⁾ | Medical Device Authority | 3 July 2023 / 2 July 2028 | Registration No. GD4900823-138256 (Serial 061809) | (b) The licensee is found to amend this licence for the purpose of deceiving or other purposes. (c) The licensee allows this licence to be misused by another person/ company. (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. (iii) This certificate does not exempt any other regulatory requirements applicable to the medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). | Complied |
| Class | Class D ⁽¹⁾ | | | | | | | | | | |
| Group | System ⁽²⁾ | | | | | | | | | | |
| 10. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="1216 1411 1307 1769"> <tr> <td>Class</td> <td>Class A⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>System⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | System ⁽²⁾ | Medical Device Authority | 14 January 2021 / 13 January 2026 | Registration No. IVDA3524821-52345 (Serial 038369) | (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | System ⁽²⁾ | | | | | | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance | | | | |
|-------|------------------------|---|------------------------------|--------------------------|---|--------------------------|--------------------------|---------------------------|---|--|----------|
| 11. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="837 1411 933 1769"> <tr> <td data-bbox="837 1579 885 1769">Class</td> <td data-bbox="837 1411 885 1579">Class A⁽¹⁾</td> </tr> <tr> <td data-bbox="885 1579 933 1769">Group</td> <td data-bbox="885 1411 933 1579">System⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | System ⁽²⁾ | Medical Device Authority | 2 June 2021 / 1 June 2026 | Registration No. IVDA2274021-62454 (Serial No. 040328) | (iii) It is the responsibility of the Establishment to ensure that the medical device complies with any other requirements of the law. This certificate does not exclude any regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. (iii) It is the responsibility of the Establishment to ensure that the medical device complies with any other requirements of the law. This certificate does not exclude any regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | System ⁽²⁾ | | | | | | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance | | | | |
|-------|------------------------|---|------------------------------|--------------------------|---|--------------------------|--------------------------|-------------------------------------|---|--|----------|
| 12. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" style="margin-left: 20px;"> <tr> <td>Class</td> <td>Class A⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>Family⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Family ⁽²⁾ | Medical Device Authority | 31 December 2022 / 30 December 2027 | Registration No. IVDA58833100018 (Serial No. 054429) | <p>(i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions.</p> <p>(ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable.</p> <p>(iii) This certificate does not exempt any other regulatory requirements applicable to the medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984).</p> | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Family ⁽²⁾ | | | | | | | | | | |
| 13. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" style="margin-left: 20px;"> <tr> <td>Class</td> <td>Class A⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>Family⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Family ⁽²⁾ | Medical Device Authority | 21 February 2019 / 20 February 2024 | Registration No. GMD56812995919A (Serial No. 027155) | <p>(i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions.</p> <p>(ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable.</p> | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Family ⁽²⁾ | | | | | | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance | | | | |
|-------|------------------------|---|------------------------------|--------------------------|---|---|--------------------------|---------------------------------------|-------------------------------------|---|----------|
| 14. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="842 1413 932 1771"> <tr> <td data-bbox="842 1585 884 1771">Class</td> <td data-bbox="842 1413 884 1585">Class A⁽¹⁾</td> </tr> <tr> <td data-bbox="884 1585 932 1771">Group</td> <td data-bbox="884 1413 932 1585">System⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | System ⁽²⁾ | Medical Device Authority | 27 September 2023 / 26 September 2028 | Registration No. IVDA5888823-148862 | (iii) It is the responsibility of the Establishment to ensure that the medical device complies with any other requirements of the law. This certificate does not exclude any regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | System ⁽²⁾ | | | | | | | | | | |
| | | | | | | (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. (iii) This certificate does not exempt any other regulatory requirements applicable to the medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Certificate No. | Major conditions imposed | Status of compliance | | | | |
|-------|------------------------|--|------------------------------|--------------------------|------------------------------------|--------------------------|--------------------------|----------------------------|---|---|----------|
| 15. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="469 1413 560 1771"> <tr> <td>Class</td> <td>Class A⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>Single⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Single ⁽²⁾ | Medical Device Authority | 1 July 2020 / 30 June 2025 | Registration No. IVDA3370920-44536 (Serial 035549) No. | (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. (iii) It is the responsibility of the Establishment to ensure that the medical device complies with any other requirements of the law. This certificate does not exclude any regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Single ⁽²⁾ | | | | | | | | | | |
| 16. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="1142 1413 1233 1771"> <tr> <td>Class</td> <td>Class A⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>Single⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Single ⁽²⁾ | Medical Device Authority | 1 July 2020 / 30 June 2025 | Registration No. IVDA3970920-44525 (Serial 035550) No. | (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Single ⁽²⁾ | | | | | | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance | | | | |
|-------|------------------------|---|------------------------------|--------------------------|---|--------------------------|--------------------------|-----------------------------|---|--|----------|
| 17. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="839 1411 932 1769"> <tr> <td data-bbox="839 1581 884 1769">Class</td> <td data-bbox="839 1411 884 1581">Class A⁽¹⁾</td> </tr> <tr> <td data-bbox="884 1581 932 1769">Group</td> <td data-bbox="884 1411 932 1581">Family⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Family ⁽²⁾ | Medical Device Authority | 28 July 2020 / 27 July 2025 | Registration No. IVDA9618520-45303 (Serial No. 035875) | (iii) It is the responsibility of the Establishment to ensure that the medical device complies with any other requirements of the law. This certificate does not exclude any regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. (iii) It is the responsibility of the Establishment to ensure that the medical device complies with any other requirements of the law. This certificate does not exclude any regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Family ⁽²⁾ | | | | | | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Certificate No. | Major conditions imposed | Status of compliance | | | | |
|-------|------------------------|---|------------------------------|--------------------------|------------------------------------|--------------------------|--------------------------|-------------------------------|--|---|----------|
| 18. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="470 1411 566 1769"> <tr> <td>Class</td> <td>Class A⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>Single⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Single ⁽²⁾ | Medical Device Authority | 29 April 2023 / 28 April 2028 | Registration No. IVDA1452623-129081 (Serial No. 058427) | (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. (iii) This certificate does not exempt any other regulatory requirements applicable to the medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Single ⁽²⁾ | | | | | | | | | | |
| 19. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="1029 1411 1125 1769"> <tr> <td>Class</td> <td>Class A⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>Family⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Family ⁽²⁾ | Medical Device Authority | 27 April 2023 / 26 April 2028 | Registration No. IVDA1643857517 (Serial No. 057434) | (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Family ⁽²⁾ | | | | | | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance | | | | |
|-------|------------------------|---|------------------------------|--------------------------|---|--------------------------|--------------------------|-----------------------------|---|--|----------|
| 20. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="730 1413 820 1771"> <tr> <td data-bbox="730 1585 772 1771">Class</td> <td data-bbox="730 1413 772 1585">Class A⁽¹⁾</td> </tr> <tr> <td data-bbox="772 1585 820 1771">Group</td> <td data-bbox="772 1413 820 1585">Single⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Single ⁽²⁾ | Medical Device Authority | 28 July 2020 / 27 July 2025 | Registration No. IVDA9534920-45293 (Serial No. 035876) | (iii) This certificate does not exempt any other regulatory requirements applicable to the medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. (iii) It is the responsibility of the Establishment to ensure that the medical device complies with any other requirements of the law. This certificate does not exclude any regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Single ⁽²⁾ | | | | | | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Certificate No. | Major conditions imposed | Status of compliance | | | | |
|-------|------------------------|---|------------------------------|--------------------------|------------------------------------|--------------------------|--------------------------|-------------------------------------|---|---|----------|
| 21. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="467 1411 558 1769"> <tr> <td>Class</td> <td>Class A⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>Single⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Single ⁽²⁾ | Medical Device Authority | 10 May 2023 / 9 May 2028 | Registration No. IVD67096360317 A (Serial 058900) No. | (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. (iii) This certificate does not exempt any other regulatory requirements applicable to the medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Single ⁽²⁾ | | | | | | | | | | |
| 22. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="1029 1411 1120 1769"> <tr> <td>Class</td> <td>Class A⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>Single⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Single ⁽²⁾ | Medical Device Authority | 2 September 2020 / 1 September 2025 | Registration No. IVDA2754920-46236 (Serial 036325) No. | (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Single ⁽²⁾ | | | | | | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance | | | | |
|-------|------------------------|---|------------------------------|--------------------------|---|--------------------------|--------------------------|-------------------------------------|--|--|----------|
| 23. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="842 1413 932 1771"> <tr> <td data-bbox="842 1585 884 1771">Class</td> <td data-bbox="842 1413 884 1585">Class A⁽¹⁾</td> </tr> <tr> <td data-bbox="884 1585 932 1771">Group</td> <td data-bbox="884 1413 932 1585">Single⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Single ⁽²⁾ | Medical Device Authority | 13 February 2020 / 12 February 2025 | Registration No. IVDA2401020-39936 (Serial No. 033645) | (iii) It is the responsibility of the Establishment to ensure that the medical device complies with any other requirements of the law. This certificate does not exclude any regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. (iii) It is the responsibility of the Establishment to ensure that the medical device complies with any other requirements of the law. This certificate does not exclude any regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Single ⁽²⁾ | | | | | | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance | | | | | | | | |
|------------|------------------------------------|---|------------------------------|--------------------------|---|--------------------------|--------------------------|-------------------------------------|---|--|--------------------------|---------------------------------------|---|---|----------|
| 24. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Class</td> <td>Class A⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>Single⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Single ⁽²⁾ | Medical Device Authority | 19 November 2019 / 18 November 2024 | Registration No. IVDA5551319-36234 (Serial No. 032039) | <p>(i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions.</p> <p>(ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable.</p> <p>(iii) It is the responsibility of the Establishment to ensure that the medical device complies with any other requirements of the law. This certificate does not exclude any regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984).</p> | Complied | | | | |
| Class | Class A ⁽¹⁾ | | | | | | | | | | | | | | |
| Group | Single ⁽²⁾ | | | | | | | | | | | | | | |
| 25. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Class</td> <td>Class A⁽¹⁾</td> </tr> <tr> <td>Group</td> <td>Single⁽²⁾</td> </tr> <tr> <td>Discipline</td> <td>Histology/ Cytology</td> </tr> <tr> <td>Category</td> <td>Histology/ Cytology Reagents</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Single ⁽²⁾ | Discipline | Histology/ Cytology | Category | Histology/ Cytology Reagents | Medical Device Authority | 18 September 2022 / 17 September 2027 | Registration No. IVD34069273917 A (Serial No. 051663) | <p>(i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions.</p> <p>(ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable.</p> | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | | | | | |
| Group | Single ⁽²⁾ | | | | | | | | | | | | | | |
| Discipline | Histology/ Cytology | | | | | | | | | | | | | | |
| Category | Histology/ Cytology Reagents | | | | | | | | | | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance | | | | |
|-------|------------------------|---|------------------------------|--------------------------|---|--------------------------|--------------------------|---------------------------------|---|--|----------|
| 26. | Matrix Optics | Medical Device Registration Certificate pursuant to Section 5(1) of the MDA: <table border="1" data-bbox="847 1413 940 1771"> <tr> <td data-bbox="847 1682 892 1771">Class</td> <td data-bbox="847 1413 892 1682">Class A⁽¹⁾</td> </tr> <tr> <td data-bbox="892 1682 940 1771">Group</td> <td data-bbox="892 1413 940 1682">Single⁽²⁾</td> </tr> </table> | Class | Class A ⁽¹⁾ | Group | Single ⁽²⁾ | Medical Device Authority | 20 August 2023 / 19 August 2028 | Registration No. IVD71660250617 A (Serial No. 064003) | (iii) It is the responsibility of the Establishment to ensure that the medical device complies with any other requirements of the law. This certificate does not exclude any regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). (i) The Medical Device Authority may cancel the Medical Device Registration or take legal action if the Establishment fails to comply with any medical device registration conditions. (ii) Medical Device Registration Certificate issued by the Medical Device Authority shall not be transferable or assignable. (iii) This certificate does not exempt any other regulatory requirements applicable to medical device (for examples: Medical Device containing scheduled poison is subjected to the Poisons Act 1952; medical devices using ionizing radiation is subjected to the Atomic Energy Licensing Act 1984). | Complied |
| Class | Class A ⁽¹⁾ | | | | | | | | | | |
| Group | Single ⁽²⁾ | | | | | | | | | | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|---------------|---|------------------------------|---------------------------|--|--|----------------------|
| 27. | Matrix Optics | <p>Certificate of Registration of Company for government procurement matters</p> <p>The individuals authorized by the company to manage the government procurement matters are as follows:</p> <p>(i) Mr. Lyn Meng Keong (General Manager)</p> <p>(ii) Ms. Maya Sari Binti Ahmat Arbi (Technical Manager)</p> <p>(iii) Mr. Akmal Hakim bin Yukhanis (Technical Support Engineer)</p> <p>(iv) Mr. Mohamad Azahar bin Abdul Hamid (Technical Support Engineer)</p> <p>(v) Mr. Mohammad Zahiruddin bin Zainal Abidin (Technical Support Engineer)</p> <p>(vi) Mr. Muhammad Aqil Arif bin Zaharinuddin (Sales Executive)</p> <p>(vii) Mr. Muhammad Amirul Shafiq bin Shufrin (Technical Support Engineer)</p> <p>(viii) Mr. Parthiban A/L Sathappan (Product Application Specialist)</p> <p>(ix) Mrs. Noor Erwani Azura Binti Shuhaimi (Sales Admin)</p> <p>(x) Mrs. Nurul Hafnaz Binti Zulkifli (Product Application Specialist)</p> | Ministry of Finance | 30 May 2023 / 29 May 2026 | <p>Certificate No.: K11701527613539055</p> <p>Registration Reference No.: 357-00043457</p> | <p>(i) Any changes to the information submitted by Matrix Optics to the Ministry of Finance must be updated online at Modul Kemaskini Profil at www.eperolehan.gov.my within 21 days from the date of occurrence of such change and a failure to do so may result in action such as item (iii) below.</p> <p>(ii) Matrix Optics is required to ensure that the fields which have been registered under this certificate do not overlap with the fields which have been approved for such companies which:</p> <p>(a) Have the same owner or Board of Directors, management and employees; or</p> <p>(b) Operate at the same premise.</p> <p>(iii) Failure to comply with the conditions of registration and/or field codes may result in the suspension or cancellation of the registration of Matrix Optics and disciplinary action including blacklisted without any notice taken against Matrix Optics, the owner and Board of Directors if it is found that the information given is not true.</p> | Complied |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|---------|--|------------------------------|--------------------------|---|---|----------------------|
| | | | | | | <p>(iv) The registration of Matrix Optics will be suspended or cancelled if it is found that Matrix Optics has committed an offence as follows:</p> <p>(a) It/ its owner/ director/ any of the management members have committed a crime and found to be guilty by the courts of Malaysia or outside Malaysia or suffer from civil liability.</p> <p>(b) It withdraws the offer before the tender is considered or reject an offer.</p> <p>(c) It fails to perform its contractual obligations for contracts which have been signed with the government.</p> <p>(d) It is found to have amended its Certificate of Registration of Company for purposes of fraud.</p> <p>(e) It is found to have allowed its Certificate of Registration of Company to be misused by other individuals/companies.</p> <p>(f) It is found to be involved in price fixing with other companies while participating in a government tender or subcontract without prior consent from the relevant government agency.</p> | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|---------------|--|------------------------------|---|---|--|----------------------|
| 28. | Matrix Optics | Wholesaler's Poisons Licence (Type B Licence – to import, store and sell by wholesale such poisons as may be specified in such licence) granted to Mr. Parthiban A/L Sathappan ⁽⁴⁾ of Matrix Optics pursuant to Section 26(2) of the Poisons Act, 1952 (Act 366) (" Poisons Act ") | Selangor Health Department | 12 January 2023 / 31 December 2023 [^] | Licence No. 013193 Register No. BB0504/2023 | (v) Matrix Optics is required to submit an application for renewal of registration three months* prior to the expiry of the registration period. In the event Mr. Parthiban A/L Sathappan changes work place or resign in the following manner: (i) Resign as a licence holder in a firm/company and works in a different firm/company in the same country. (ii) Resign as a licence holder in a firm/company and works in a different firm/company in a different country. (iii) Changes address of work place/business address but there is no change to the firm which he is working in. The licence holder is required to take the following actions:- (a) The authority that issues the poison license, which is the Licensing Officer of any state or the Federal Territory (" Licensing Officer ") ⁽⁵⁾ , must be informed about the change of name or address of the place of work/business before any change is carried out. The licence holder is also required to explain to the officer the action which the licence holder is proposing to take for the stored poisons at the firm where the licence holder will resign as a licence holder; | Complied |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|---------|--|------------------------------|--------------------------|---|---|----------------------|
| | | | | | | <p>(b) The licence holder is also required to submit his license to the Licensing Officer for cancellation. The license cancellation will be carried out when there is a change as mentioned in sub-paragraphs (i) to (iii) in the above paragraph.</p> <p>(c) Together with the surrender of licence holder's license to be cancelled, the licence holder can apply for a new licence from the same Licensing Officer if the place where the licence holder resigned and the firm where the licence holder wants to work/conduct business are located in the same state. But, if the firm where the licence holder resigns and the firm where the licence holder wants to work/conduct business have addresses in different states, the licence holder is required to apply for a new licence from the Licensing Officer of the State where the licence holder wants to work/conduct business.</p> | |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|------------------|------------------|--|-------------------------------------|---|---|---|----------------------|
| | | | | | | (d) It is the licence holder's responsibility to observe that the place of business does not continue to use the licence holder's licence unless licence holder as a licensee are still working at that place of business. If the licence holder does not take the actions mentioned above for any inappropriate or illegal practices regarding poison carried out in the firm/company or place of business where the licence holder last worked, court action will be taken against the licence holder and the firm/company by confiscating the poisons stored in the firm/company or place of business. The licence holder will also face difficulties in applying for a new license for a new place of practice. | |
| Singapore | | | | | | | |
| 29. | Crest Innovation | Licence to manufacture, possess for sale or deal in ionising irradiating apparatus and/or radioactive material | National Environment Agency ("NEA") | 20 February 2023 / 1 October ⁽⁶⁾ | IR1/2023/00209 | Qualified Person: Koh Chee Chung (Director) (i) Notice of every transaction involving any irradiating apparatus or radioactive material must be submitted to the NEA's Radiation Protection and Nuclear Science Group in the form and manner specified by the NEA. | Complied |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|------------------|--|------------------------------|--|---|--|----------------------|
| | | | | | | <p>(ii) Licensee must ensure that any sealed source supplied has a valid certificate (not older than 12 months from the date of testing at the time the source is supplied) to show each sealed source has been tested for leakage of radioactive material and has been found free of such leakage, and provide such a certificate to the person to whom the sealed source is supplied to.</p> <p>(iii) Licensee must ensure that any individual carrying out installation, demonstration, servicing, operation or maintenance of any irradiating apparatus authorised under this licence has been appropriately trained to do so.</p> <p>(iv) Licensee must ensure that any individual handling any radioactive material authorised under this licence must be suitably trained to do so.</p> | |
| 30. | Crest Innovation | Licence to keep or possess an ionising irradiating apparatus and/or radioactive material for use (other than sale) | NEA | 20 February 2023 / 1 July ⁽⁷⁾ | IR2/2023/01020 | <p>Qualified Person: Koh Chee Chung (Director)</p> <p>(i) For cancellation of this licence, documentary proof of the whereabouts of the apparatus or materials is required to be submitted.</p> | Complied |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|-----|------------------|--|------------------------------|---------------------------|---|--|----------------------|
| | | | | | | <p>(ii) Licensee must ensure that authorised irradiating apparatus and radioactive materials are not used for irradiation of human beings or administered to human beings unless authorised to be used for medical, dental or research (involving human subjects) purposes.</p> <p>(iii) Licensee must ensure that any individual handling any radioactive material authorised under this licence must be suitably trained to do so.</p> <p>(iv) Licensee must ensure that authorised irradiating apparatus and radioactive materials are not used for irradiation of human beings or administered to human beings unless authorised to be used for medical, dental or research (involving human subjects) purposes.</p> | |
| 31. | Crest Innovation | Licence to manufacture or deal in non-ionising irradiating apparatus | NEA | 5 July 2023 / 4 July 2024 | N1/05000/0001 | <p>(i) The licensee shall be subject to suspension or cancellation at any time without compensation and without notice by the Director-General of Environmental Protection in the event of but not limited to the following events: (a) breach of any restrictions or conditions subject to which it was issued; or (b) contravention of any of the provisions of the Radiation Protection Act or the Regulations thereunder.</p> | Complied |

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

| No. | Company | Description of licence / permit / approval / certificate | Approving authority / issuer | Issue date / Expiry date | Licence / Permit / Registration / Certificate No. | Major conditions imposed | Status of compliance |
|------------------------|----------------|---|--|--------------------------------------|---|---|----------------------|
| <u>Thailand</u> | | | | | | | |
| 32. | Crest Thailand | Registration certificate to import medical devices pursuant to the Medical Devices Act B.E. 2551 (2008) | Food and Drug Administration of Thailand | 14 September 2023 / 31 December 2027 | KorTor. SorNor. 277/2556 | (ii) Application for the renewal of this licence shall be made not later than one month before the expiry date as appearing in this N1 licence. The licence holder is only permitted to import the medical devices according to the following categories: (i) clinical laboratory; (ii) pathology; and (iii) surgery. | Complied |
| <u>PRC</u> | | | | | | | |
| 33. | Crest Suzhou | Registration Certificate of Customs Declaration Unit (consignee and consignor of import and export goods) | Customs of Suzhou Industrial Park Administrative Committee | 1 June 2017 / no date of expiry | 3205230540 | Crest Suzhou shall submit its annual report of Customs Declaration Unit Registration Information to the Customs of Suzhou Industrial Park Administrative Committee prior to 30 June every year. | Complied |

Notes:

- * Based on the renewal portal for the submission of the application for renewal of registration, the company may only submit its renewal application once the 90 days' renewal period has commenced.
- ^ Matrix Optics had on 4 January 2024 submitted an application for a new Wholesaler's Poisons Licence (Type B Licence). The new licence is expected to be issued within 1 month from the date of submission of the application.
- (1) Pursuant to the Medical Device Guidance Document, Guidance on the Rules of Classification for General Medical Devices (MDA/GD/0009) (Second Edition) published as at 9 May 2022, medical devices are classified into one of 4 classes based on the risk associated to it at the point of usage (i.e. the risk to patients, users and other persons). The purposes of such risk-based classification are (a) to make sure that the regulatory controls applied to a medical device are proportionate to risk, (b) to assist a manufacturer to allocate its medical device to an appropriate risk class and (c) regulatory authorities have the responsibility of ruling upon matters of interpretation for a particular medical device. The 4 classes of general medical devices are (a) Class A, Low Risk, which device examples are surgical retractors / tongue depressors; (b) Class B, Low-moderate Risk, which device examples are hypodermic needle / suction equipment; (c) Class C, Moderate-high Risk, which device examples are lung ventilator / orthopedic implants and (d) Class D, High Risk, which device examples are heart valves / implantable defibrillator.

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

- (2) Pursuant to the Medical Device Guidance Document, Guidance on the Product Grouping (MDA/GD/0005) (First Edition) published as at October 2013, a medical device that is categorised as:
- “Single” is a medical device from a manufacturer identified by a medical device proprietary name with a specific intended purpose. It is sold as a distinct packaged entity and may be offered in a range of package sizes;
 - “System” is a medical device comprising of a number of constituent-components that are: (a) from the same manufacturer; (b) intended to be used in combination to complete a common intended purpose; (c) compatible when used as a “System”; and (d) sold under a “System” name or the labelling, instruction for use, brochures or catalogues for each constituent component states that the constituent component is intended for use with the “System”;
 - “Family” is a collection of medical devices and each medical device “Family” member: (a) is from the same manufacturer; (b) is of the same risk classification; (c) has the same medical device proprietary name; (d) has a common intended purpose; (e) has the same design and manufacturing process; and (f) has variations that are within the scope of the permissible variants. A characteristic of a medical device may be considered a permissible variant if: (a) the physical design and construction of the medical devices are the same, or very similar; (b) the manufacturing processes for the medical devices are the same, or very similar; (c) the intended purpose of the medical devices is the same; and (d) the risk profile of the medical devices, taking into account the aforementioned factors, is the same.
- (3) The Certificate of Registration in Form V1 is required pursuant to regulation 97(C) of the Guideline of Approval of Electrical Equipment issued by the Energy Commission in exercise of power conferred by the Electricity Supply Act, which provides that any person who manufactures or imports any equipment under regulation 97 shall apply to be registered with the Energy Commission. Regulation 97 states that subject to, among others, regulation 97(C), no person shall manufacture, import, display, sell or advertise (a) any domestic equipment; (b) any low voltage equipment which is usually sold direct to the general public; or (c) any low voltage equipment which does not require special skills in its operation, unless the equipment is approved by the Energy Commission.
- (4) Mr. Parthiban A/L Sathappan is an employee of Matrix Optics. Pursuant to section 26(2) of the Poisons Act, a Type B licence may be issued to any person whom the Licensing Officer may consider to be a fit and proper person to hold such licence, or issued to a responsible officer of a company incorporated under the Companies Act 2016. Such licence shall be personal to the licensee named therein and shall not in any case, be transferable to another person and no licensee shall authorize the sale of any poison by any person other than the person named therein or otherwise than under his personal supervision, provided that the Licensing Officer, if he sees fit, may amend on a licence the address of the premises at which the person licensed carries on the business or profession in respect of which he is licensed. If the licensee contravenes any term or condition of such licence, he/she shall be guilty of an offence against the Poisons Act. Any person guilty of an offence against the Poisons Act, for which no other penalty is specifically provided by the Poisons Act or by any regulations made thereunder, shall be punishable by a fine not exceeding RM50,000.00 or by imprisonment for a term not exceeding five (5) years, or to both, provided that if the act or omission with which such person is charged, is in the opinion of the court of such a nature as to amount to wilful default or culpable negligence, which endangered or was likely to endanger human life, such person shall be liable, on conviction, to a fine not exceeding RM200,000.00 or to imprisonment for a term not exceeding ten (10) years, or to both.
- (5) “Licensing Officer” means a person appointed to be a Licensing Officer under section 26 of the Poisons Act and includes the Director General of Health, Malaysia.
- (6) 1 October being the anniversary date of the licence. An annual fee must be paid before the anniversary date stated in the licence (e.g. if the anniversary date is on 1 October, the annual fee payment due date is on 30 September of each year).
- (7) 1 July being the anniversary date of the licence. An annual fee must be paid before the anniversary date stated in the licence (e.g. if the anniversary date is on 1 July, the annual fee payment due date is on 30 June of each year).

ANNEXURE A OUR MAJOR LICENCES, PERMITS AND APPROVALS (Cont'd)

Aside from the major licences, permits and approvals as listed above, our Group also maintains business premise licences for our premises in various locations where we conduct our business activities. These business premise licences are renewable on an annual basis. The application and renewal process is an ongoing process and at any one point in time, there will be premises which business premise licences are in the midst of being applied for or renewed.

[The rest of this page has been intentionally left blank]